Welcome to our dedicated page for Centessa Pharmaceuticals Plc SEC filings (Ticker: CNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Centessa Pharmaceuticals plc (CNTA) SEC filings page provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and related exhibits. As a Nasdaq-listed issuer with ordinary shares and American Depositary Shares registered under Section 12(b) of the Exchange Act, Centessa files documents that describe material events, financing transactions, governance matters and other information relevant to CNTA shareholders.
Recent Forms 8‑K detail items such as underwriting agreements for public offerings of American Depositary Shares, an amended and restated at-the-market sales agreement, financial results for quarterly periods, and the clearance of an Investigational New Drug (IND) application for ORX142. Filings also cover outcomes of the company’s annual general meeting, including director elections, auditor re-appointment and share allotment authorities, as well as executive employment arrangements reported under Item 5.02.
Through this page, users can review how Centessa reports progress and risks around its clinical-stage orexin receptor 2 (OX2R) agonist pipeline, capital-raising activities, and other significant corporate actions. Forms 8‑K that reference press releases often include clinical and financial updates, while accompanying exhibits such as sales agreements, underwriting agreements and legal opinions provide additional detail on transaction structures and securities law matters.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, sections and implications, helping readers quickly understand complex documents such as offering-related 8‑Ks and governance disclosures. Investors can use this resource to monitor CNTA’s regulatory reporting history, track new filings as they appear on EDGAR in near real time, and identify information relevant to their own analysis of the company.
Centessa (NASDAQ:CNTA) Form 4 reports that Chief Business Officer Gregory M. Weinhoff exercised 10,000 options at $3.85 and immediately sold the same 10,000 ordinary shares on 06/25/2025 through a Rule 10b5-1 plan.
The shares were disposed at a weighted-average price of $13.8642, yielding roughly $139 k in gross proceeds and an implied ~$10 per-share spread. After the transactions he still owns 122,279 ordinary shares (≈8 % reduction versus post-exercise balance) and 65,000 unexercised options. The sale exceeds the 5 % materiality threshold for insider trades, making the activity noteworthy for investors tracking executive sentiment.
Centessa Pharmaceuticals (NASDAQ: CNTA) Form 4 shows General Counsel Iqbal J. Hussain exercised 12,000 stock options at $5.84 and immediately sold the same number of ordinary shares at a weighted-average $14.02 on 06/24/2025 under a Rule 10b5-1 plan.
Post-transaction, Hussain’s direct ownership declined by ~10% to 105,386 shares; he also holds 5,500 shares indirectly and 291,559 unexercised options.
- Gross sale proceeds ≈ $168.2 K.
- Sale represents >5% of insider’s pre-sale direct holdings, meeting materiality threshold.
- No impact on share count or dilution.
Insider selling by a senior legal officer can be viewed as a potential sentiment headwind, though execution under a pre-arranged 10b5-1 plan mitigates timing concerns.